Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
Claudia Angela Maria Fulgenzi,Bernhard Scheiner,Antonio D’Alessio,Aman Mehan,Giulia F. Manfredi,Ciro Celsa,Naoshi Nishida,Celina Ang,Thomas U. Marron,Linda Wu,Anwaar Saeed,Brooke Wietharn,Antonella Cammarota,Tiziana Pressiani,Matthias Pinter,Rohini Sharma,Jaekyung Cheon,Yi-Hsiang Huang,Pei-Chang Lee,Samuel Phen,Anuhya Gampa,Anjana Pillai,Andrea Napolitano,Caterina Vivaldi,Francesca Salani,Gianluca Masi,Marianna Silletta,Federica Lo Prinzi,Emanuela Di Giacomo,Bruno Vincenzi,Dominik Bettinger,Robert Thimme,Arndt Vogel,Martin Schönlein,Johann von Felden,Kornelius Schulze,Henning Wege,Peter R. Galle,Mario Pirisi,Joong-Won Park,Masatoshi Kudo,Lorenza Rimassa,Amit G. Singal,Paul El Tomb,Susanna Ulahannan,Alessandro Parisi,Hong Jae Chon,Wei-Fan Hsu,Giorgia Ghittoni,Calogero Cammà,Benedetta Stefanini,Franco Trevisani,Edoardo G. Giannini,Alessio Cortellini,David James Pinato
DOI: https://doi.org/10.1001/jamaoncol.2024.2166
IF: 33.006
2024-07-18
JAMA Oncology
Abstract:Importance Whether patients with Child-Pugh class B (CP-B) cancer with unresectable hepatocellular carcinoma (uHCC) benefit from active anticancer treatment vs best supportive care (BSC) is debated. Objective To evaluate the association of immune checkpoint inhibitor (ICI)–based therapies vs BSC with overall survival (OS) of patients with uHCC and CP-B liver dysfunction. Design, Setting, and Participants This retrospective, multicenter, international clinical case series examined data of patients with CP-B with uHCC who were receiving first-line ICI-based regimens from September 2017 to December 2022 whose data were extracted from an international consortium and compared with a cohort of patients with CP-B receiving BSC. Patients were treated in tertiary care centers across Europe, US, and Asia in routine clinical practice. After applying the inclusion criteria, 187 and 156 patients were left in the ICI and BSC groups, respectively. The propensity score was calculated for the following variables: age, alpha-fetoprotein levels, Child-Pugh score, extrahepatic spread, portal vein tumor thrombosis, cirrhosis, ascites, and baseline Eastern Cooperative Oncology Group performance status. Exposures Patients in the ICI group received first-line systemic therapy with either atezolizumab plus bevacizumab (A+B) (n = 141) or nivolumab (n = 46). Main Outcomes and Measures OS in the inverse probability of treatment weighting (IPTW) populations was the main outcome, and it was estimated with Kaplan-Meier method; univariable Cox regression test was used to make comparisons between the 2 groups. Results The median age was 66 (IQR, 61-72) and 73 (IQR, 66-81) years in the ICI (33 women [18%]) and BSC groups (41 women [26%]), respectively. In the IPTW populations, median OS was significantly longer in the ICI group (7.50 months; 95% CI, 5.62-11.15) compared with BSC (4.04 months; 95% CI, 3.03-5.03; hazard ratio, 0.59; 95% CI, 0.43-0.80; P < .001). Multivariable analysis confirmed that ICI exposure was associated with a reduction of approximately 50% in the risk of death (hazard ratio, 0.55; 95% CI, 0.35-0.86; P < .001), and the presence of portal vein tumor thrombosis, an Eastern Cooperative Oncology Group performance score of greater than 1, and alpha-fetoprotein levels of 400 ng/mL or greater were associated with increased risk of death. Conclusions and Relevance The results of this case series provide comparative evidence of improved survival in association with ICI treatment compared with BSC in patients with uHCC with CP-B liver dysfunction.
oncology